|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-319.97/-0.13
|
Enterprise Value
3.23M
|
Balance Sheet |
Book Value Per Share
2.36
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
5.00K
|
Operating Revenue Per Share
1.83
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/10/31 18:31 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. |